Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 785,414 | 694,381 | 580,074 | 724,531 | 761,515 |
| Marketable Securities | 340,431 | 476,577 | 572,017 | 567,006 | 512,253 |
| Receivables | 572,498 | 610,222 | 597,913 | 461,316 | 419,622 |
| Inventories | 1,032,159 | 975,546 | 918,921 | 894,083 | 839,460 |
| Other current assets | 224,806 | 193,391 | 173,180 | 104,521 | 149,851 |
| TOTAL | $2,955,308 | $2,950,117 | $2,842,105 | $2,751,457 | $2,682,701 |
| Non-Current Assets | |||||
| PPE Net | 1,067,156 | 1,067,278 | 1,068,142 | 1,073,366 | 1,051,821 |
| Investments And Advances | 548,002 | 385,777 | 340,635 | 333,835 | 372,302 |
| Intangibles | 498,675 | 506,542 | 522,188 | 534,768 | 550,223 |
| Other Non-Current Assets | 1,689,022 | 1,653,458 | 1,660,625 | 1,681,648 | 1,606,993 |
| TOTAL | $3,802,855 | $3,613,055 | $3,591,590 | $3,623,617 | $3,581,339 |
| Total Assets | $6,758,163 | $6,563,172 | $6,433,695 | $6,375,074 | $6,264,040 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 493,398 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 669,825 | 597,231 | 598,231 | 588,884 | 521,020 |
| TOTAL | $1,163,223 | $597,231 | $598,231 | $588,884 | $521,020 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 698,043 | 1,183,114 | 1,176,421 | 1,183,034 | 1,174,506 |
| TOTAL | $698,043 | $1,183,114 | $1,176,421 | $1,183,034 | $1,174,506 |
| Total Liabilities | $1,861,266 | $1,780,345 | $1,774,652 | $1,771,918 | $1,695,526 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 188,368 | 188,175 | 187,701 | 186,529 | 185,849 |
| Common Shares | 188 | 188 | 188 | 186 | 186 |
| Retained earnings | -641,929 | -682,307 | -738,347 | -789,199 | -788,949 |
| Other shareholders' equity | -4,136 | -29,010 | -20,671 | -12,726 | 21,424 |
| TOTAL | $4,896,897 | $4,782,827 | $4,659,043 | $4,603,156 | $4,568,514 |
| Total Liabilities And Equity | $6,758,163 | $6,563,172 | $6,433,695 | $6,375,074 | $6,264,040 |